Differential Bio
Differential Bio runs a robotic high-throughput lab and trains AI models on the resulting fermentation data, then serves them through a web platform where bioprocess teams simulate unlimited virtual experiments to optimize media, strains and scale-up.
What is Differential Bio?
Differential Bio is a German biotech company that sells what it calls a Virtual Scale-up Platform for bioprocess optimization. The idea behind it is compact: fermentation development is slow and expensive because every hypothesis costs a physical run, so the company shrinks the experiment and moves the iteration into software.
Three pieces make that work. First, a robotic laboratory generates the data, running thousands of parallel 96-well microtiter experiments with real-time growth monitoring, and reproducing at microliter scale the stress factors a strain would meet in an industrial fermenter. The company sums this up as we scale down to scale up. Second, specialized models are trained on that wet-lab data to predict outcomes such as biomass growth and protein expression. Third, the resulting in-silico model is delivered through a web platform where the client runs unlimited virtual experiments.
On the platform, work moves through four stages: configure an optimization goal and the parameter ranges to explore, predict the KPIs of interest across simulated conditions, analyze and compare the resulting fermentation scenarios, then implement the selected parameters and scale up. Addressable KPIs include biomass (cell dry weight, optical density, CFU/mL), titer-rate-yield, cell viability, and product purity and stability.
Engagement starts with scoping which media components and process parameters matter. From there a client either sends its proprietary strain to Differential Bio's robotic lab, or supplies its own or historical data. Seven use cases are named on the site: media optimization, strain selection, industrial side- and waste-stream screening, genotype-to-phenotype linking, scale-up prediction, downstream processing optimization, and shelf-life stability.
The published evidence is narrow but unusually concrete. With Canadian probiotics maker CanBiocin, a commercial Limosilactobacillus reuteri strain gained 34.1% in biomass yield at 27.6% lower media cost, after screening more than 3,000 formulations in under four weeks and validating the result in a 4L bioreactor. Differential Bio GmbH is based in Feldkirchen near Munich, runs a lab at the Technical University of Munich in Freising, and emerged from stealth in March 2025.
What it does
- Optimize fermentation media by exploring carbon, nitrogen and mineral sources against a defined objective
- Predict biomass, titer, rate, yield and cell viability for conditions that have never been run physically
- Compare candidate strains and check whether a genetic intervention actually delivers the intended effect
- Run multi-objective optimizations that trade yield against media cost and recipe simplicity
- Screen industrial side streams and waste streams as candidate substrates for a given strain
- De-risk a scale-up by modelling the batch before committing bioreactor time to it
- Optimize downstream processing and shelf-life stability, including cryopreservation formulations
When to use Differential Bio / When not to
A quick filter to help you decide if Differential Bio is the right fit.
When to use Differential Bio
- Fermentation and bioprocess R&D teams that want to cut the number of physical runs before committing to a scale-up batch
- Probiotics manufacturers optimizing growth media for a commercial strain, the use case Differential Bio documents in most detail
- Food, cosmetics and specialty chemicals companies moving a process from an animal-based to a plant-based medium without losing yield
- Organizations sitting on years of historical fermentation data that has never been turned into a predictive model
- Biomanufacturing startups that need scale-up evidence for investors or partners but cannot afford repeated pilot-scale runs
When not to use Differential Bio
- Anyone expecting self-service software: there is no sign-up, no trial and no published price, and the only route in is a sales call
- Teams working outside microbial fermentation, such as mammalian cell culture, synthetic chemistry or clinical analysis
- Buyers who need an API, a mobile app or a connector to plug results into an existing data platform, none of which exist here
- Procurement processes requiring a formal security review, since no DPA, subprocessor list or security certification is published
- Small labs looking for a cheap exploratory tool rather than a scoped project involving knowledge transfer and a data campaign
How to use Differential Bio
A typical end-to-end flow, from setup to results.
- Book a call through the site's contact form or calendar slot, which is the only available entry point
- Scope the project with the team: agree the optimization goal, share the strain and the current medium
- Choose how data will be generated, either a high-throughput campaign in Differential Bio's robotic lab or your own historical dataset
- Let the data campaign run: thousands of parallel 96-well experiments with real-time growth monitoring
- Wait for the AI model that maps media inputs and process parameters to growth outcomes to be built
- Open the web platform and configure your optimization goal and the parameter ranges to explore
- Run virtual experiments and read the predicted KPIs, including multi-objective runs that balance yield against cost
- Compare the simulated fermentation scenarios and shortlist the formulations worth testing physically
- Validate the leading candidates in a 4L bioreactor under production-like conditions
- Collect the deliverables: media specifications, protocols and the model insights needed to implement the change
Pros & Cons
Pros
- Published, client-named results rather than generic claims: +34.1% biomass and -27.6% media cost on a commercial strain at CanBiocin
- Real experimental throughput, with more than 3,000 formulations screened in under four weeks, reported as 34 times a manual workflow
- Findings are validated physically in a 4L bioreactor, so the output is not simulation alone
- Documented client economics: 283% ROI after ten batches, with break-even reached within the first three production batches
- Results have been presented publicly alongside the client, on stage at Probiota Global 2026 in Dublin
- A clear five-step method with defined deliverables at the end, which makes the engagement easy to scope
- A European vendor under GDPR, with complete legal disclosures and a lab embedded in the Technical University of Munich ecosystem
Cons
- No public pricing of any kind: no page, no range, no billing unit, so the budget cannot be estimated before a sales call
- No self-service and no trial; the platform is reachable only after a commercial engagement
- The privacy policy covers the marketing site only and says nothing about client platform data, its retention or its location
- No DPA, no subprocessor list, no security page and no certification such as SOC 2 or ISO 27001
- Several parts of the site are unfinished: the Probiotics navigation link returns a 404 and the Request Invite buttons lead to a dead anchor
- Webflow template residue is still visible, with Lorem ipsum cards on the homepage and fictitious New York job listings on the about page
- A very young company with roughly ten people, and performance figures that come from a single public client on a single strain
Pricing & Plans
No pricing is published. Differential Bio displays no pricing page, no price range and no billing unit anywhere on its site, and states neither a free plan nor a free trial. The sole commercial entry point is a booked call, after which pricing is presumably quoted per project. The only monetary figures published are client-side returns from the CanBiocin case study, which say nothing about the price paid.
Data, GDPR & hosting
A consolidated view of how Differential Bio handles your data.
GDPR overview
Compliance is claimed explicitly: the privacy policy states that Differential Bio strictly adheres to the GDPR and to the German Digital Services Act (DDG). The controller is Differential Bio GmbH, represented by its managing director Christian Spier, and data protection requests go to info@differential.bio. The policy lists the usual rights: access to the personal data held, access to stored correspondence, withdrawal of cookie consent, rectification and completion, erasure, restriction of processing, and portability in a structured, machine-readable format. The competent supervisory authority is named as the Bavarian Commissioner for Data Protection, with a right to complain to any other authority. Being established in Germany, the company needs no Article 27 representative. No DPO is named, and no DPA or subprocessor list is published. Effective date: 4 February 2025.
Who owns the data?
The published documents say very little about ownership of customer data. The privacy policy of 4 February 2025 covers the website only: contact-form data is not passed to third parties and is kept solely for as long as it takes to answer the enquiry. A short Terms of use section on the same page claims Differential Bio's ownership of the site's own content, graphics and design. On the product side, the homepage states that data captured on a client's proprietary strain is generated with full IP protection, but that is a commercial promise, not a published clause. Nothing on the site says who owns the experimental data, the trained models or the optimization results, so ownership has to be settled in the contract.
Reuse rights
For the website, the uses are stated precisely and narrowly. Contact-form data is processed to answer the request, on the legal basis of Article 6(1)(c) GDPR, and is not shared with third parties. Audience measurement runs on Google Analytics under Article 6(1)(a), meaning consent, with IP anonymization enabled and tracking triggered only after the visitor accepts the banner; consent can be withdrawn at any time through browser settings or Google's opt-out add-on. Google acts as processor and may store that data on servers in the United States, covered by the EU-U.S. Data Privacy Framework. For the platform itself there is no published statement at all: nothing says whether a client may reuse the models or datasets produced during a project, and nothing says whether client data feeds anything beyond that client's own models. Those permissions do not exist in writing and must be negotiated.
Data retention & training
Hosting summary
There is no information about where client platform data is hosted. The site names no country, no region and no cloud provider for the experimental data, the trained models or the optimization results, and publishes no security or trust page that would cover it. The only hosting statement in the privacy policy concerns the marketing website: analytics data collected through Google Analytics may be stored on Google servers located in the United States, a transfer Google covers under the EU-U.S. Data Privacy Framework. That fact belongs to Google and describes website audience measurement, not the bioprocess platform, and it should not be read as a statement about where client data lives. The site is served behind Cloudflare on an anycast address, which says nothing about storage either. What can be established is jurisdictional rather than technical: the vendor is established in Germany, is subject to the GDPR, and names the Bavarian Commissioner for Data Protection as its supervisory authority.
Things to keep in mind
Risks and trade-offs to weigh before adopting Differential Bio.
- No price is published anywhere, so you cannot size the budget before entering a sales conversation
- The privacy policy covers only the marketing site; client platform data, its retention and its location are entirely undocumented
- The full IP protection promised on the homepage is a commercial claim with no published contractual clause behind it, and must be secured in writing
- No DPA, no subprocessor list and no security certification, which will block or slow any formal procurement review
- Performance figures come from a single public client on a single strain, so treat them as a benchmark, not as a guaranteed outcome
- The homepage metrics of 3x R&D cost reduction, four weeks and 80% titer improvement are attached to no named source or project
- Trusting a predictive model over your own experimental judgement is a real risk: the platform is designed to narrow the search space, not to remove the need for physical validation
Setup & Integrations
Technical difficulty
There is nothing to install: the platform is delivered through a browser, with no API, connector or code to integrate. The difficulty lies elsewhere. Getting started is a contractual and scientific exercise rather than a technical one, beginning with a sales call, then a scoping phase to agree which media components and process parameters to optimize. You must arrive with a strain, a reference medium and defined process objectives, and then either ship the strain to the robotic lab or supply your own historical fermentation data. The screening campaign itself is described as taking under four weeks.
Deployment
Behind Differential Bio
Fundraising
Social
Resources
All the official URLs gathered for verification and reference.
Frequently asked questions
What exactly is the Virtual Scale-up Platform?
Which KPIs can Differential Bio optimize?
Do I have to send my strain to their lab?
How much does it cost?
What results have actually been documented?
Are the predictions checked against reality?
Is there an API or a mobile app?
Who is behind the tool and where is it based?
What happens to my data under the GDPR?
Is my strain data protected?
Should you pick Differential Bio?
Differential Bio is a narrow, serious tool aimed at a narrow, serious problem. Fermentation development burns years and budget because each hypothesis has to be run physically, and the company's answer is to generate dense data in a robotic lab, train a model on it, and let the client explore the remaining design space in software. What makes the pitch credible is that the strongest claims are attached to a named client rather than left abstract: on a commercial Limosilactobacillus reuteri strain at CanBiocin, biomass yield rose 34.1% while media cost fell 27.6%, with more than 3,000 formulations screened in under four weeks and the winning formulation confirmed in a 4L bioreactor. Presenting those numbers on stage with the client, at Probiota Global 2026, is a further sign of confidence.
The reservations are commercial rather than scientific. Nothing is priced, nothing is self-service, and the only way to learn what an engagement costs is to book a call. More importantly for a data-sensitive buyer, the published legal documentation covers the marketing website and stops there: there is no data processing agreement, no subprocessor list, no retention rule for experimental data and no security certification. The full IP protection promised on the homepage is a sales statement that will need to become a contract clause. The site itself is visibly unfinished in places, with a broken navigation link, dead buttons and leftover template text.
If you already run fermentation at scale and want to cut the number of physical iterations before your next batch, this is worth a conversation, and the case study gives you a concrete benchmark to hold them to. If you are exploring on a tight budget, or need vendor documentation to clear a procurement review, it is too early.
- Choosing a selection results in a full page refresh.
- Opens in a new window.